Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

279
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
279
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

208
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and in vitro evaluation of solution-based pressurized metered-dose inhaler formulations using green propellants.

The Journal of pharmacy and pharmacology·2026
Same author

Moving Forward from "Fine Particle Fraction: The Good and the Bad".

Journal of aerosol medicine and pulmonary drug delivery·2022
Same author

Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers.

The AAPS journal·2021
Same author

Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.

AAPS PharmSciTech·2019
Same author

Characterization of Tetracycline Hydrochloride Compounded in a Miracle Mouthwash Formulation.

AAPS PharmSciTech·2019
Same author

Pressurized Metered Dose Inhaler Technology: Manufacturing.

AAPS PharmSciTech·2019
Same journal

Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System.

AAPS PharmSciTech·2026
Same journal

The Preparation and Physicochemical Characterization of a Triple Synergistic Nanoplatform Designed for Targeted Subcutaneous Delivery of Sitagliptin with Potential for β-Cell Preservation.

AAPS PharmSciTech·2026
Same journal

Repurposing Non-oncologic Drugs via Targeted Nanocarriers for Cancer Therapy: Mechanisms, Synergistic Combinations, and Clinical Translation.

AAPS PharmSciTech·2026
Same journal

Targeting Permeability Barriers By Strategic Selection of Thiol Containing Coformer for Novel Cocrystals of Metformin.

AAPS PharmSciTech·2026
Same journal

Plume Geometry Matters: Investigating the Contribution of Mass-Based Plume Geometry to Aerosol Delivery Efficiency in pMDIs.

AAPS PharmSciTech·2026
Same journal

Eigenrate-Based Thermodynamic Decomposition of Competing Release Mechanisms in Polymeric Nano- and Microspheres: The MMIR-S Framework with Arrhenius Dual-Population Burst Kinetics and Log-Normal Polydispersity Averaging.

AAPS PharmSciTech·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.7K

Advances in metered dose inhaler technology: formulation development.

Paul B Myrdal1, Poonam Sheth, Stephen W Stein

  • 1College of Pharmacy, University of Arizona, 1703 E. Mabel St., PO Box 210207, Tucson, Arizona, 85721, USA, myrdal@pharmacy.arizona.edu.

AAPS Pharmscitech
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

This review explores challenges in formulating pressurized metered dose inhalers (MDIs) for lung diseases. It examines excipient impacts on drug delivery and discusses advanced strategies for multi-drug MDI formulations.

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.3K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.7K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.3K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Respiratory Medicine

Background:

  • Pressurized metered dose inhalers (MDIs) are established devices for treating lung diseases like asthma and COPD.
  • MDI performance depends on propellant-driven atomization of drug-containing droplets for lung deposition.
  • Transitioning from CFC to HFA propellants necessitated advancements in MDI formulation and understanding of variables affecting performance.

Purpose of the Study:

  • To review challenges in formulating solution or suspension MDIs with single or multiple drugs.
  • To analyze the impact of various excipients on MDI product performance.
  • To evaluate novel formulation approaches for multi-drug MDI delivery.

Main Methods:

  • Survey of literature on MDI formulation science.
  • Analysis of physicochemical properties of common MDI excipients.
  • Evaluation of formulation strategies for single and multiple active pharmaceutical ingredients (APIs).
  • Discussion of engineered particles and drug-excipient complexes.

Main Results:

  • Excipients significantly influence MDI droplet characteristics, stability, and lung deposition.
  • Hydrofluoroalkane (HFA) propellants present unique formulation challenges compared to chlorofluorocarbons (CFCs).
  • Optimizing excipient selection (e.g., surfactants, cosolvents, stabilizers) is crucial for both solution and suspension MDI products.
  • Engineered particles offer potential for improved multi-drug delivery from a single MDI device.

Conclusions:

  • Successful MDI formulation requires a deep understanding of drug-excipient-propellant interactions.
  • Careful selection and characterization of excipients are critical for achieving desired aerosol performance and therapeutic efficacy.
  • Advanced formulation techniques are essential for developing next-generation MDIs, particularly for combination therapies.